Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9621080 | 0.96 | KMT2A (0.53) | HSD17B1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL9621112 | 0.96 | KMT2A (0.53) | HSD17B1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL1160042 | 0.89 | ACHE (0.56) | HSD17B1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL29420327 | 0.88 | KMT2A (0.56) | KMT2AMEN1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL354177 | 0.88 | KMT2A (0.56) | KMT2AMEN1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL29420326 | 0.88 | KMT2A (0.56) | KMT2AMEN1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL8002421 | 0.87 | TNFSF11 (0.57) | HSD17B1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL1807630 | 0.87 | HSD17B1 (0.50) | HSD17B1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL2776025 | 0.87 | HSD17B1 (0.50) | HSD17B1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL30759603 | 0.87 | HSD17B1 (0.50) | HSD17B1KMT2AMEN1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1326358-A | Method of DNA vaccination | GLAXO GROUP LTD (GB) | 2001-12-12 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5618982-A | SIMPLE INDUSTRIAL PROCESS OF CATALYZING IN PRESENCE OF METALLIC PHOSPHATES | RHONE-POULENC CHIMIE (FR) | 1997-04-08 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-20250170111-A1 | PYRIDINE BASED CHALCONE ANALOGS AS THERAPEUTIC AGENTS AND USE THEREOF | QATAR UNIVERSITY (QA) | 2025-05-29 | — | — | US | disclosed |
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | disclosed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | disclosed |
| US-3980699-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-09-14 | — | — | US | disclosed |
| US-3978116-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3978124-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170111-A1 | PYRIDINE BASED CHALCONE ANALOGS AS THERAPEUTIC AGENTS AND USE THEREOF | HCCS, PDXK, NOD1 | HSD17B1 1029/4885KMT2A 4417/4885MEN1 3589/4885 |
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | BET1, BRD4, BAZ2A | HSD17B1 4513/4885KMT2A 848/4885MEN1 990/4885 |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | HSD17B1 3247/4885KMT2A 2663/4885MEN1 1378/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | HSD17B1 4175/4885KMT2A 1372/4885MEN1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.